StockpollyBeta
Get App
Popularity #2,305
IMVT · NASDAQ · Biotechnology

Immunovant (IMVT)

Developing imeroprubart across six IgG-driven autoimmune diseases.

$37.29
After hours0.00 (0.00%)
At close$37.29(+0.30%)

In millions of USD, except per-share figures

In millionsQ2 FY24Sep 2023Q3 FY24Dec 2023Q4 FY24Mar 2024Q1 FY25Jun 2024Q2 FY25Sep 2024Q3 FY25Dec 2024Q4 FY25Mar 2025Q1 FY26Jun 2025Q2 FY26Sep 2025Q3 FY26Dec 2025Q4 FY26Mar 2026Q1 FY27Jun 2026
Revenue000000000007
Cost of revenue000000000000
Gross profit000000000007
62628194116114114127132114160160
Research & development4848667597959410111499142143
141315191820202618151718
General & administrative141315191820202618151718
Operating income−62−62−81−94−116−114−114−127−132−114−160−153
4106773886590
Interest income498765766580
Other non-operating income−4−10−6−7−7−3−8−8−6−5−90
Income before tax−58−52−75−87−109−111−106−120−126−109−151−153
Income tax expense0000001112−30
Net income from continuing operations−59−51−75−87−109−111−106−121−127−111−148−153
Net income−59−51−75−87−109−111−106−121−127−111−148−153
EPS, basic−$0.45−$0.36−$0.52−$0.60−$0.74−$0.76−$0.64−$0.71−$0.73−$0.61−$0.73−$0.75
EPS, diluted−$0.45−$0.36−$0.52−$0.60−$0.74−$0.76−$0.64−$0.71−$0.73−$0.61−$0.73−$0.75
Weighted average shares, basic131145145146146147152171174182204206
Weighted average shares, diluted131145145146146147152171174182204206
EBITDA−58−51−75−87−109−111−106−120−126−109−151−153
Depreciation & amortization000000000000
EBIT−58−52−75−87−109−111−106−120−126−109−151−153